AKT1 and breast carcinoma: Lee et al. reported that in the breast cancer FAM83A possibly contributes in exerting resistance to tyrosine kinase inhibitors via activating epidermal growth factor receptor (EGFR)/PI3K/AKT signaling pathway via interacting with c-RAF and phosphatidylinositol 3 kinase p85.